Caffrey P B, Frenkel G D
Department of Biological Sciences, Rutgers University, Newark, NJ 07102, USA.
Anticancer Res. 1998 Jul-Aug;18(4C):3017-20.
Human ovarian tumors (derived from A2780 cells), growing as subcutaneous xenografts in immunodeficient mice, develop melphalan-resistant cells after a single treatment of the tumor-bearing animal with the drug [Caffrey, Zhang and Frenkel, submitted for publication]. Treatment of the animals with selenite by i.p. injection prevented the development of primary resistance to melphalan as well as cross-resistance to cisplatin. Selenite treatment also prevented the melphalan-induced increase in the cellular level of glutathione. In contrast, selenite administered s.c. or in drinking water had relatively little effect on the development of resistance. The results in this animal model suggest that selenite may be clinically useful in preventing the development of drug resistance during chemotherapy of cancer.
源自A2780细胞的人卵巢肿瘤，在免疫缺陷小鼠体内以皮下异种移植物的形式生长，在用美法仑单次治疗荷瘤动物后，会产生美法仑耐药细胞[卡弗里、张和弗伦克尔，待发表]。通过腹腔注射亚硒酸盐治疗动物可预防对美法仑的原发性耐药以及对顺铂的交叉耐药的发生。亚硒酸盐治疗还可防止美法仑诱导的细胞内谷胱甘肽水平升高。相比之下，皮下注射或饮水给予亚硒酸盐对耐药性的发展影响相对较小。该动物模型的结果表明，亚硒酸盐在预防癌症化疗期间耐药性的发展方面可能具有临床应用价值。
